# DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE

Presenter: Sarah Bradley, MS, CGC Genetic Counselor, NYS Newborn Screening Program

Authors: S. Bradley, D. Kronn, B. Vogel, M. Caggana, J. Orsini, K. Harris, K. D'Aco, A. Iglesias, P.A. Levy, L. Estrela, R. Miller, and P. Kishnani

#### OUTLINE

- Review of Pompe disease
- Newborn screening for Pompe
- New York State (NYS) method
- Follow-up preparations
  - Diagnostic algorithm
  - Management recommendations/considerations
  - Case definitions

#### POMPE REVIEW

- Pompe disease is a lysosomal storage disorder
- Caused by mutations in the *GAA* gene, which codes for the alpha-glucosidase (GAA) enzyme
- AKAs: Glycogen storage disorder type II, Acid Maltase Deficiency, Acid Alpha-glucosidase deficiency
- Autosomal recessive
- Incidence: ~ 1 in 17,000 births, panethnic

### POMPE REVIEW

#### • Two phenotypic sub-types:

- Early-onset: results from complete or near absence of GAA enzyme
  - Symptoms begin at birth or shortly thereafter
  - Symptoms: hypotonia, hypertrophic cardiomyopathy, failure to thrive, and respiratory insufficiency
- Late-onset: results from partial deficiency of GAA enzyme
  - Age of onset if variable from first few months of life to adulthood
  - Symptoms: slowly progressive myopathy primarily involving skeletal muscle
  - Usually no cardiac involvement with this form

### POMPE REVIEW

• Treatment is enzyme replacement therapy (ERT)

- Myozyme or Lumizyme
- Improved survival and function
- CRIM status is important consideration
  - <u>Cross Reactive Immunologic Material</u>
  - It is the endogenous GAA enzyme produced by most Pompe patients
  - CRIM negative = no residual GAA activity
    - 20% of patients
    - They produce anti-rhGAA antibodies and do not respond to ERT unless immune tolerance induction is done prior to or concurrent with ERT
  - CRIM positive = GAA enzyme activity > 1%
    - These patients usually do not produce anti-rhGAA antibodies and have better response to ERT

## NEWBORN SCREENING FOR POMPE DISEASE

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Discretionary Advisory Committee on Heritable Disorders in Newborns and Children 5600 Fishers Lane, Room 18A19 Rockville, Maryland 20857 (301) 443-1080 – Phone (301) 480-1312 – Fax www.hrsa.gov/heritabledisorderscommittee

June 3, 2013

The Honorable Kathleen Sebelius Secretary of Health and Human Services 200 Independence Avenue, S.W. Washington, DC 20201

Dear Secretary Sebelius:

The Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (the Committee) is charged with making systematic evidence-based and peerreviewed recommendations that include heritable disorders that have the potential to significantly impact public health for which all newborns should be screened. During the Committee's May 2013 meeting, the Committee reviewed the objective evidence report for the nominated heritable disorder –Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency). Based on this report which included a public health impact assessment and Committee deliberations, the Committee voted to recommend that you update and expand the Recommended Uniform Screening Panel (RUSP) to include the addition of Pompe Disease.

#### NYS METHOD OF SCREENING FOR POMPE

- 1<sup>st</sup> tier: measure GAA enzyme activity via MS/MS
- $2^{nd}$  tier: sequencing of GAA gene

#### FOLLOW-UP PREPARATIONS

• New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services (NYMAC) sponsored a Pompe disease symposium November 1-2, 2013 in Valhalla, NY


• Attendees included metabolic geneticists from mid-Atlantic region, genetic counselors, and newborn screening personnel from several states, as well as an expert on Pompe disease, Dr. Priya Kishnani from Duke University

#### FOLLOW-UP PREPARATIONS

- 1. Preliminary diagnostic algorithms and management recommendations were created by NBS staff prior to NYMAC Pompe symposium
- 2. These were reviewed with the group at the meeting
- 3. They were revised using the group's feedback
- 4. Revised versions were sent to the attendees after the meeting via email for additional feedback
- 5. The documents were revised again
- 6. One final review with Dr. Priya Kishnani and Dr. David Kronn
- 7. Final edits made

#### DIAGNOSTIC ALGORITHM

- Goals of the algorithm:
  - To answer the question, does this baby have Pompe disease?
  - To recommend the minimum lab work and evaluations necessary in order to answer that question



#### MANAGEMENT PROTOCOLS

• Goals of the recommendations:

- To provide medical management recommendations for infants and children with Pompe disease identified on newborn screening
  - These are intended to cover what is minimally needed, and are not a substitute for good clinical judgment
  - The most recent published guidelines were from 2006 when the diagnosis most often occurred because an infant or child was symptomatic, and when ERT was still considered an emerging treatment (Kishnani PS, Steiner RD, Bali D et al. (2006))
- To ensure that recommended tests and evaluations are feasible

#### MANAGEMENT PROTOCOLS

- Recommendations for Determining Cross Reactive Immunologic Material (CRIM) Status
- Recommendations & Considerations for Initiating ERT
- Table 1. Evaluations for Monitoring of <u>Asymptomatic Patients with Pompe Disease</u>
- Table 2. Evaluations for Monitoring of <u>Symptomatic</u> Individuals with Pompe Disease

## EXAMPLE: RECOMMENDED EVALUATIONS FOR MONITORING OF <u>Asymptomatic</u> Patients with Pompe Disease

TABLE 1. THE FOLLOWING ARE EVALUATIONS FOR CONSIDERATION WHEN PROVIDING MEDICAL CARE FOR ASYMPTOMATIC INDIVIDUALS (NO CARDIAC INVOLVEMENT OR OTHER SIGNS/SYMPTOMS AT BIRTH) WITH POMPE DISEASE IDENTIFIED ON NBS:

Table 1. Evaluations for Monitoring of Asymptomatic Patients with Pompe Disease						
Evaluation	At diagnosis	As clinically indicated*	If abnormal, consider initiating ERT X			
Clinical examination with attention to muscle tone	х	x				
Establish medical home for patient	Х					
Determination of CRIM status (via GAA genotype and/or measuring GAA activity in fibroblasts)	х					
Cardiology evaluation	Х	Х	X			
<ul> <li>ECG and 24-hour ECG, If indicated</li> <li>Echocardiogram</li> </ul>						
Laboratory studies						
<ul> <li>Blood GAA enzyme analysis (skin as needed)</li> </ul>	Х	x	X**			
GAA gene sequencing	Х	x				
• Urine Glc <sub>4</sub>	Х	x				
• CK	Х	x				
• ALT	Х					
• AST	Х					
Pulmonary evaluation		Х	X			
Swallow study		Х	X			
Nutrition/GI evaluation		Х	x			
Ophthalmology evaluation		Х	Х			
Audiology evaluation	via NBS	Х				
Developmental Pediatrics/Early Intervention evaluation		х	X			
Bone density		Х				
Anesthesiology		x				
Genetic counseling	Х	Х				

# CASE DEFINITIONS

#### Pompe Disease Newborn Screening Case Definitions

Pompe Disease (aka Acid Alpha-Glucosidase Deficiency)	Category	Mutation Status	GAA Enzyme Activity	Cardiac Involvement	Clinical Symptoms/Lab Findings	CRIM Status	Diagnosis Code
	Definite, early- onset Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	Yes	Present	Negative	POMP10
	Definite, early- onset Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	Yes	Present	Positive	POMP11
	Definite, early- onset Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	Yes	Not present	Negative	POMP12
	Definite, early- onset Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	Yes	Not present	Positive	POMP13
	Definite, early- onset Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	No	Present	Negative	POMP14
	Definite, early- onset Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	No	Present	Positive	POMP15
	Definite, Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	No	Not present	Negative	POMP16
	Definite, Pompe disease	2 disease-causing mutations or positive skin or muscle bx	Low	No	Not present	Positive	POMP17
	Definite, early- onset Pompe disease	1 disease-causing mutation*	Low	Yes	Present	Negative	POMP18
	Definite, early- onset Pompe disease	1 disease-causing mutation*	Low	Yes	Present	Positive	POMP19

Definite, early- onset Pompe disease	1 disease-causing mutation*	Low	Yes	Not present	Negative	POMP20
Definite, early- onset Pompe disease	1 disease-causing mutation*	Low	Yes	Not present	Positive	POMP21
Definite, early- onset Pompe disease	1 disease-causing mutation*	Low	No	Present	Negative	POMP22
Definite, early- onset Pompe disease	1 disease-causing mutation*	Low	No	Present	Positive	POMP23
Possible disease	1 disease-causing mutation*	Low	No	Not present	N/A	POMP30
Possible disease	≥ 1 VUS	Low	No	Not present	N/A	POMP31
No disease	No disease-causing mutations	Normal	No	Not present	N/A	POMP40
No disease	1 or 2 pseudodeficiency alleles only (no mutation)	Low	No	Not present	N/A	POMP41
No disease	1 disease-causing mutation	Normal	No	Not present	N/A	POMP42
No disease	Polymorphisms only (no mutations)	Normal	No	Not present	N/A	POMP49

\* With or without variants of uncertain significance (VUS) or pseudodeficiency allele.

# **QUESTIONS?**

Sarah Bradley, MS, CGC Genetic Counselor NYS Newborn Screening Program <u>Sarah.bradley@health.ny.gov</u> 518-408-1302